FI3386506T3 - Kv3-kanavien modulaattoreita kivun hoitamiseksi - Google Patents

Kv3-kanavien modulaattoreita kivun hoitamiseksi Download PDF

Info

Publication number
FI3386506T3
FI3386506T3 FIEP16813020.1T FI16813020T FI3386506T3 FI 3386506 T3 FI3386506 T3 FI 3386506T3 FI 16813020 T FI16813020 T FI 16813020T FI 3386506 T3 FI3386506 T3 FI 3386506T3
Authority
FI
Finland
Prior art keywords
tai
metyyli
yyli
etyyli
oksi
Prior art date
Application number
FIEP16813020.1T
Other languages
English (en)
Finnish (fi)
Inventor
Charles Large
Giuseppe Alvaro
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Application granted granted Critical
Publication of FI3386506T3 publication Critical patent/FI3386506T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/315Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FIEP16813020.1T 2015-12-10 2016-12-09 Kv3-kanavien modulaattoreita kivun hoitamiseksi FI3386506T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Publications (1)

Publication Number Publication Date
FI3386506T3 true FI3386506T3 (fi) 2024-04-23

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16813020.1T FI3386506T3 (fi) 2015-12-10 2016-12-09 Kv3-kanavien modulaattoreita kivun hoitamiseksi

Country Status (21)

Country Link
US (3) US11147813B2 (enExample)
EP (1) EP3386506B1 (enExample)
JP (3) JP7149847B2 (enExample)
KR (1) KR102812887B1 (enExample)
CN (2) CN118267386A (enExample)
AU (1) AU2016367239B2 (enExample)
BR (1) BR112018011700B1 (enExample)
CA (1) CA3005302A1 (enExample)
DK (1) DK3386506T3 (enExample)
EA (1) EA038059B1 (enExample)
ES (1) ES2974902T3 (enExample)
FI (1) FI3386506T3 (enExample)
GB (1) GB201521751D0 (enExample)
HR (1) HRP20240497T1 (enExample)
HU (1) HUE066879T2 (enExample)
IL (1) IL259717B (enExample)
MX (1) MX385578B (enExample)
PL (1) PL3386506T3 (enExample)
PT (1) PT3386506T (enExample)
SG (1) SG11201804123VA (enExample)
WO (1) WO2017098254A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
MX2021004386A (es) * 2018-10-16 2021-06-04 Autifony Therapeutics Ltd Compuestos novedosos.
US12358901B2 (en) * 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
AR116898A1 (es) * 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
JP7539377B2 (ja) 2018-11-30 2024-08-23 大塚製薬株式会社 てんかん治療用複素環化合物
NZ790491A (en) 2020-02-06 2025-12-19 Autifony Therapeutics Ltd Kv3 modulators
MX2024001899A (es) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd Moduladores del canal de potasio.
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013405A (es) 2008-06-06 2011-02-15 Ucb Pharma Sa Compuestos que comprenden un grupo ciclobutoxi.
IL219628A (en) * 2009-12-11 2014-09-30 Autifony Therapeutics Ltd Imidazolidinedione derivatives
CA2817205C (en) * 2010-12-06 2020-04-07 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
JP6008953B2 (ja) 2011-06-07 2016-10-19 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
PL2788339T3 (pl) 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
WO2013175211A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
CN108472288B (zh) 2024-05-28
GB201521751D0 (en) 2016-01-27
IL259717A (en) 2018-07-31
CN118267386A (zh) 2024-07-02
EP3386506A1 (en) 2018-10-17
MX2018007074A (es) 2018-12-12
KR20180097549A (ko) 2018-08-31
PT3386506T (pt) 2024-03-28
KR102812887B1 (ko) 2025-05-26
CA3005302A1 (en) 2017-06-15
US11147813B2 (en) 2021-10-19
CN108472288A (zh) 2018-08-31
IL259717B (en) 2021-05-31
HUE066879T2 (hu) 2024-09-28
BR112018011700A2 (pt) 2018-11-27
AU2016367239A1 (en) 2018-06-07
HRP20240497T1 (hr) 2024-08-16
ES2974902T3 (es) 2024-07-02
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
JP2019506367A (ja) 2019-03-07
US11944623B2 (en) 2024-04-02
BR112018011700B1 (pt) 2023-12-26
DK3386506T3 (da) 2024-05-06
US20190000848A1 (en) 2019-01-03
SG11201804123VA (en) 2018-06-28
JP2025003958A (ja) 2025-01-14
PL3386506T3 (pl) 2024-06-03
EP3386506B1 (en) 2024-01-24
JP7149847B2 (ja) 2022-10-07
EA201891377A1 (ru) 2019-01-31
JP2022141699A (ja) 2022-09-29
EA038059B1 (ru) 2021-06-30
WO2017098254A1 (en) 2017-06-15
US20250017925A1 (en) 2025-01-16
AU2016367239B2 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
FI3386506T3 (fi) Kv3-kanavien modulaattoreita kivun hoitamiseksi
ES2998396T3 (en) Substituted tetrahydrofurans as modulators of sodium channels
CY1124414T1 (el) Αναστολεις του υποδοχεα τελεστη αυξησης ινοβλαστων
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
WO2010025295A3 (en) Compounds that modulate intracellular calcium
AU2022297367B2 (en) Diacylglyercol kinase modulating compounds
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
WO2009035818A8 (en) Compounds that modulate intracellular calcium
MX374346B (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
EA201100992A1 (ru) Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
SI4103566T1 (sl) Kondenzirane pirimidin spojine kot modulatorji kcc2
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
CL2017003112A1 (es) Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
AU2022299051B2 (en) Diacylglyercol kinase modulating compounds
WO2019089676A8 (en) Antagonists of the muscarinic acetylcholine receptor m4
MY200738A (en) Pyrazole magl inhibitors
EP3888653A4 (en) NOVEL CRYSTAL OF (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDIN-3-YL)-4-FLUORO-1H-IMIDAZOLE-5-YL]-7-[5-CHLORO-2-(1H -TETRAZOLE-1-YL)PHENYL]-2,3-DIHYDROINDOLIZINE-5(1H)-ONE
MX2009009364A (es) Compuestos de indol y benzotiofeno como moduladores del receptor de histamina h3.
CL2009001330A1 (es) Compuestos derivados de ciano-3-oxoisoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno de dolor.
EA201401265A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и оксикам
WO2008124524A3 (en) Aryl sulfonamide compounds as modulators of the cck2 receptor
CO7111286A2 (es) Sal de l-malato de derivados de 2,7-diaza-espiro[4,s]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de girelina
EP3114112A4 (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol